Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders

BACKGROUND: Major efforts have been made in the last decade to develop and improve therapies for proximal spinal muscular atrophy (SMA). The introduction of Nusinersen/Spinraza™ as an antisense oligonucleotide therapy, Onasemnogene abeparvovec/Zolgensma™ as an AAV9-based gene therapy and Risdiplam/E...

Descripción completa

Detalles Bibliográficos
Autores principales: Jablonka, Sibylle, Hennlein, Luisa, Sendtner, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725368/
https://www.ncbi.nlm.nih.gov/pubmed/34983696
http://dx.doi.org/10.1186/s42466-021-00162-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725368/
https://www.ncbi.nlm.nih.gov/pubmed/34983696
http://dx.doi.org/10.1186/s42466-021-00162-9

Ejemplares similares